(HealthDay)—Lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 radioligand therapy added to standard care is beneficial for patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, according to a study published online June 23 in the New England Journal of Medicine. Oliver Sartor, M.D., from Tulane University in New Orleans, and colleagues conducted an international, phase 3 trial involving […]